From the Division of Gastroenterology and Hepatology, University of Maryland School of Medicine.
Department of Medicine, University of Maryland Midtown Medical Center.
Cancer J. 2023;29(5):249-258. doi: 10.1097/PPO.0000000000000682.
Hepatocellular carcinoma (HCC) represents a significant global burden, with management complicated by its heterogeneity, varying presentation, and relative resistance to therapy. Recent advances in the understanding of the genetic, molecular, and immunological underpinnings of HCC have allowed a detailed classification of these tumors, with resultant implications for diagnosis, prognostication, and selection of appropriate treatments. Through the correlation of genomic features with histopathology and clinical outcomes, we are moving toward a comprehensive and unifying framework to guide our diagnostic and therapeutic approach to HCC.
肝细胞癌 (HCC) 是一种全球性的重大负担，其管理因肿瘤的异质性、不同表现和相对耐药性而变得复杂。近年来，人们对 HCC 的遗传、分子和免疫学基础有了更深入的了解，这使得对这些肿瘤进行详细分类成为可能，从而对诊断、预后和选择合适的治疗方法产生了影响。通过将基因组特征与组织病理学和临床结果相关联，我们正在朝着一个全面统一的框架发展，以指导我们对 HCC 的诊断和治疗方法。
